Saturday 7 May | 14.30-16.30 5 CEST
Faculty: Piet Dirix (Belgium) and Alan Dal Pra (United States)
Summary: Innovations in radiation techniques could establish “moderate” hypofractionation as a new standard. Recently, “extreme” hypofractionation was recognized as a valid alternative in selected patients. Arguably, such SBRT treatments will form the future of prostate cancer radiation therapy. We will discuss the current level of evidence and current indications, differences in delineations and conclude with planning and image-guided delivery.